STOCK TITAN

Eton Pharmaceutcials (ETON) Stock Price, News & Analysis

ETON NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
30 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+44.3% close of August 14, 2026
1-year change
+273.3% closing prices, November 20, 2025 to November 20, 2026
1-month change
+21.2% closing prices, October 20, 2026 to November 20, 2026

Company Description

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a pharmaceutical company that focuses on developing and commercializing treatments for rare diseases. According to multiple company press releases, Eton concentrates on products for patients with serious, often ultra-rare conditions, with a particular emphasis on pediatric endocrinology and other endocrine and metabolic disorders.

The company is described in SEC filings as Eton Pharmaceuticals, Inc., and its press releases state that it is based in Deer Park, Illinois. Eton is included in the Russell 2000 and Russell 3000 indexes, as disclosed in a June 27, 2025 press release and a related Form 8-K, which positions it among publicly traded small-cap U.S. companies.

Rare disease product portfolio

In its 2025 news releases, Eton states that it has eight commercial rare disease products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. These products are used in rare endocrine and metabolic conditions, including adrenocortical insufficiency and other ultra-rare disorders, as described in the company’s press releases.

Eton’s May 28, 2025 press release notes that KHINDIVI (hydrocortisone) Oral Solution is approved by the U.S. Food and Drug Administration (FDA) as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency. The same release explains that KHINDIVI is the first and only FDA-approved hydrocortisone oral solution and is designed to provide accurate, titratable dosing in a ready-to-use liquid form. Eton also commercializes ALKINDI SPRINKLE (hydrocortisone) oral granules, which are FDA-approved for pediatric patients with adrenocortical insufficiency.

Press releases in 2025 describe the relaunch and commercial growth of INCRELEX and GALZIN. Eton reports that it acquired INCRELEX from Ipsen S.A., as detailed in an amended Form 8-K filed on November 18, 2025, which provides historical financial statements and pro forma financial information related to that acquisition. The company also reports that it relaunched GALZIN after acquiring the product and that both brands have become important contributors to product revenue.

Pipeline and late-stage product candidates

Eton states that it has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector. These candidates are repeatedly referenced in the company’s 2025 press releases as part of its rare disease pipeline.

In a July 8, 2025 press release and corresponding Form 8-K, Eton reports that the FDA has accepted the New Drug Application (NDA) for ET-600, a proprietary patented formulation of desmopressin oral solution, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date. The company describes ET-600 as being developed for the treatment of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), and notes that ET-600 is protected by a formulation patent extending to 2044, with an additional patent application under review.

Other pipeline updates in 2025 press releases include preparation for clinical studies of ET-700 and development work on a revised KHINDIVI formulation intended to support potential label expansion for younger pediatric patients, subject to regulatory review.

Focus on pediatric endocrinology and ultra-rare conditions

Throughout its communications, Eton emphasizes its focus on rare diseases and pediatric endocrinology. Press releases describe its commercial team as rare disease specialists and highlight the company’s engagement with pediatric endocrinology societies and patient advocacy organizations. Eton’s products and pipeline address conditions such as adrenocortical insufficiency, central diabetes insipidus, and other rare endocrine and metabolic disorders, as described in the company’s own materials.

The company’s May 28, 2025 KHINDIVI approval press release notes that adrenocortical insufficiency is a rare but serious condition in which the adrenal glands do not produce sufficient cortisol. Eton estimates there are more than 5,000 adrenal insufficiency patients in the United States between the ages of 5 and 17, and it states expectations for peak sales of KHINDIVI combined with ALKINDI SPRINKLE, illustrating the commercial significance of this therapeutic area for the company.

Public company status and financial reporting

Eton trades on the Nasdaq under the ticker symbol ETON. SEC Form 8-K filings in 2025 show that the company regularly reports quarterly financial results and uses non-GAAP measures such as Adjusted EBITDA to evaluate its operations. The November 6, 2025 Form 8-K, for example, references a press release announcing financial results for the quarter ended September 30, 2025 and discusses the rationale for presenting Adjusted EBITDA as a supplemental performance metric.

The company’s 2025 financial results press releases report sequential growth in product sales over multiple quarters and attribute this growth to increased sales of ALKINDI SPRINKLE and Carglumic Acid, as well as revenue contributions from INCRELEX and GALZIN. Eton also discloses research and development expenses related to its pipeline programs, including ET-600, ET-700, and ET-800, and general and administrative expenses associated with commercial launches and expanded headcount.

Corporate developments and governance

In a June 20, 2025 Form 8-K, Eton reports a change in its independent registered public accounting firm, noting the dismissal of Crowe LLP and the appointment of Grant Thornton LLP as the new auditor for the fiscal year ended December 31, 2025. The filing states that there were no disagreements with the prior auditor on accounting principles, financial statement disclosure, or audit procedures during the relevant period.

The company’s inclusion in the Russell 2000 and Russell 3000 indexes, disclosed in a June 27, 2025 press release and related Form 8-K, reflects its status as a publicly traded small-cap company. Eton also participates in healthcare investor conferences hosted by firms such as Wells Fargo, Craig-Hallum, and Piper Sandler, as noted in several 2025 press releases, which highlights its ongoing engagement with the investment community.

Summary

According to its own disclosures, Eton Pharmaceuticals, Inc. is a Nasdaq-listed pharmaceutical company headquartered in Deer Park, Illinois, with a business focused on rare disease therapies. It has a portfolio of eight commercial rare disease products and a pipeline of late-stage candidates, including ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector. The company emphasizes pediatric endocrinology and ultra-rare conditions, reports regular financial results through SEC filings and press releases, and is a constituent of the Russell 2000 and Russell 3000 indexes.

Stock Performance

$60.85
-0.83%
-0.51
Last updated: at
+273.3%
Performance 1 year
28.8M
Shares outstanding As of November 2, 2026.

Eton Pharmaceutcials (ETON) closed at $60.85 on November 20, 2026. Over the past 12 months, the price has gained 273.3%.

See what a $1,000 investment in ETON would be worth today

Average down calculator for ETON

ETON Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Eton Pharmaceutcials has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, earnings date. View all ETON news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
213,221
Shares Sold
15
Transactions
Most Recent Transaction
Erdogan-Trinkaus Ipek (Chief Commercial Officer) sold 3,500 shares at an average of $67.41 on November 10, 2026

Insider selling at Eton Pharmaceutcials over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Eton Pharmaceutcials generated $80.0M in revenue in FY2025, retaining a 53.5% gross margin, operating income reached -$844K (-1.1% operating margin), and net income was -$4.6M, reflecting a -5.8% net profit margin. The company generated $10.5M in operating cash flow. The current ratio was 1.57, measuring current assets divided by current liabilities.

$80.0M
Revenue (FY2025)
-$4.6M
Net Income (FY2025)
$10.5M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Clinical

Additional study arms

Eton plans additional study arms to test faster-release ET-700 formulations during 2027; sponsor: Eton Pharmaceutcials, Inc.
H1
2027
H1 2027 Regulatory

FDA PAS decision

U.S. FDA decision on Eton's PAS seeking KHINDIVI label expansion to younger pediatric adrenal insufficiency patients (H1 2027).
Q1
2027
Q1 2027 Clinical

Phase 2 enrollment start

University of Chicago‑sponsored Phase 2 (up to 20 patients, ages 2–18) across 3 sites; enrollment/dosing targeted Q1 2027.
YEAR
2027
2027 Clinical

Potential pivotal study start

Contingent start of pivotal ET-700 study if H2 2026 topline results positive; potential initiation Jan-Apr 2027.
JAN
10
January 10, 2027 Regulatory

VALTOCO exclusivity expiry

VALTOCO’s orphan drug exclusivity expires in the U.S. on Jan 10, 2027, potentially enabling full approval for LIBERVANT ages 12+.
APR
2027
April 2027 Product

Commercial availability

Eton anticipates U.S. commercial availability of LIBERVANT in April 2027, pending final FDA approval and launch preparations.
APR
2027
April 2027 Product

LIBERVANT launch

Targeted April 2027 launch of LIBERVANT, contingent on FDA approval. Eton Pharmaceutcials, Inc. to commercialize upon clearance.
H2
2027
H2 2027 Regulatory

ASN-001 NDA submission

Eton plans NDA submission for ASN-001 in 2H 2027 for topical timolol in infantile hemangiomas; US rights licensed from Auson.
YEAR
2028
2028 Regulatory

ASN-001 U.S. launch

Potential FDA approval and U.S. commercial launch of ASN-001 expected in 2028; could serve 20,000–30,000 annual patients.

Eton Pharmaceutcials has 9 upcoming scheduled events. The next event, "Additional study arms", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the ETON stock price.

Short Interest History

Last 12 Months

Short interest in Eton Pharmaceutcials (ETON) currently stands at 2.0 million shares, up 2.2% from the previous reporting period, representing 7.2% of the float. Since November 2025, short interest has decreased by 20.5%.

Days to Cover History

Last 12 Months

Days to cover for Eton Pharmaceutcials (ETON) currently stands at 5.4 days, up 64.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 36.6%. Across the settlements charted above, it has ranged from 2.0 to 11.9 days.

ETON Company Profile & Sector Positioning

Eton Pharmaceutcials (ETON) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing ETON often look at related companies in the same sector, including BioCryst Pharmaceuticals Inc (BCRX), ANI Pharmaceuticals, Inc. (ANIP), Alvotech (ALVO), Pacira BioSciences, Inc. (PCRX), and Phibro Animal Health Corporation (PAHC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ETON's relative position within its industry.

Frequently Asked Questions

The current stock price of Eton Pharmaceutcials (ETON) is $60.85 as of November 20, 2026.

The market cap of Eton Pharmaceutcials (ETON) is approximately $1.8B. Learn more about what market capitalization means .

The FY2025 revenue of Eton Pharmaceutcials (ETON) is $80.0M, from its most recent completed fiscal year.

The FY2025 net income of Eton Pharmaceutcials (ETON) is -$4.6M, from its most recent completed fiscal year.

The operating cash flow of Eton Pharmaceutcials (ETON) is $10.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Eton Pharmaceutcials (ETON) is -5.8% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Eton Pharmaceutcials (ETON) is -1.1% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Eton Pharmaceutcials (ETON) is 53.5% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Eton Pharmaceutcials (ETON), current assets divided by current liabilities, was 1.57 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Eton Pharmaceutcials (ETON) is $42.7M for FY2025, its most recent completed fiscal year.

The operating income of Eton Pharmaceutcials (ETON) is -$844K for FY2025, its most recent completed fiscal year. Learn about operating income.

Eton Pharmaceuticals, Inc. focuses on developing and commercializing treatments for rare diseases. Company press releases describe Eton as a pharmaceutical company with a portfolio of commercial rare disease products and late-stage product candidates, many of which address endocrine and metabolic conditions in pediatric and other specialized patient populations.

Eton Pharmaceuticals is listed on the Nasdaq stock market under the ticker symbol ETON. This is stated in multiple company press releases and confirmed in the headers of its SEC Form 8-K filings.

Eton Pharmaceuticals’ SEC Form 8-K filings list its address in Deer Park, Illinois. The filings identify the company as Eton Pharmaceuticals, Inc. with offices in Deer Park, Illinois, indicating that this is its corporate location.

According to several 2025 press releases, Eton states that it has eight commercial rare disease products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. These products are used in rare endocrine and metabolic conditions as described by the company.

In a May 28, 2025 press release, Eton describes KHINDIVI (hydrocortisone) Oral Solution as an FDA-approved replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency. The company states that KHINDIVI is the first and only FDA-approved hydrocortisone oral solution and is designed to provide accurate, titratable dosing in a ready-to-use liquid form.

Eton’s July 8, 2025 press release and related Form 8-K state that ET-600 is a proprietary formulation of desmopressin oral solution developed for the treatment of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D). The company reports that the FDA has accepted its New Drug Application for ET-600 and assigned a PDUFA target action date.

Company press releases in 2025 state that Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector. These candidates are part of the company’s rare disease pipeline and are referenced in multiple news releases.

Yes. A June 27, 2025 press release and corresponding Form 8-K state that Eton Pharmaceuticals will be added to the Russell 3000 and small-cap Russell 2000 indexes as part of the 2025 Russell indexes reconstitution.

Across its 2025 press releases, Eton repeatedly describes itself as an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company highlights pediatric endocrinology and ultra-rare endocrine and metabolic conditions as key areas of focus.

In its November 6, 2025 Form 8-K and related press release, Eton discusses net revenue, product sales, gross profit, research and development expenses, general and administrative expenses, and Adjusted EBITDA. The filing explains that Adjusted EBITDA is used by management and investors as a supplemental non-GAAP measure to evaluate operating performance across periods.